Biomarkers in ANCA-Associated Vasculitis
- First Online:
- Cite this article as:
- Lally, L. & Spiera, R.F. Curr Rheumatol Rep (2013) 15: 363. doi:10.1007/s11926-013-0363-x
Despite recent advances in the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), relapse remains common and patients often experience a variable clinical course after initial treatment. New biomarkers are needed to aid the management of these complex diseases. Discoveries regarding the pathogenesis of AAV, from the importance both of activated B and T cells and the alternative complement pathway to genomic data, may lay the groundwork for identification of novel biomarkers.